March 20th, 2013

Concord, MA/Houston, TX -(BUSINESS WIRE)–Alcyone Life Sciences, Inc., a privately held biopharmaceutical device company focusing on developing products for the treatment of difficult neuropathological conditions, and DNAtrix, Inc., a privately held biotechnology company developing virus-based immunotherapy products for cancer, today announced a collaboration to investigate Alcyone”s Microcatheter System for delivery of therapeutics for brain tumor. Under the collaboration, Alcyone and DNAtrix will establish proof of concept for a proprietary direct delivery device in a preclinical setting.

“We are pleased to announce this collaboration between Alcyone’s platform technology and a promising experimental brain cancer therapy from DNAtrix” said Rich Upton, General Partner, Harbor Light Capital Partners and Board Director at Alcyone Lifescience, Inc,.

A prerequisite for the efficacy of any cancer drug is that it reaches the tumor in therapeutic concentrations. For brain tumors, it is often desirable and more effective to deliver anti-cancer agents such as DNAtrix’s oncolytic immunotherapy, directly to the tumor mass using catheters or needles. Alycone’s Microcatheter System is specifically designed to provide enhanced reliability for direct intratumoral delivery.

“We are excited to be working with Alcyone on the development of a uniquedeliveryr system for direct intratumoral delivery” said Frank Tufaro, Ph.D. CEO of DNAtrix. “We feel this could provide an important option for neurosurgeons as we develop additional products for treating a variety of brain tumors, including brain metastases.

“We look forward to working with the DNAtrix team to improve treatment for a disease where little options exist for patients,” said David Donabedian, Ph.D., Independent Board Director, Alcyone Lifesciences. Dr. Donabedian adds, “Targeted delivery to the brain, particularly to brain tumors, is an impor ant challenge, and Alcyone’s platform technology may greatly enhance the PK profile of a variety of active molecules.”

About Glioblastoma

Glioblastoma is the most common and most aggressive malignant primary brain tumor in humans that is resistant to conventional therapies. It accounts for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. The current standard of care – surgery, radiotherapy and chemotherapy – has extended the overall median survival to only 14.6 months. Treatment of glioblastoma remains an unmet medical need wherein new therapeutic modalities are essential requisite for impacting the course of this disease.

About A cyone LifeSciences

Alcyone Lifesciences is a Concord, MA based private biopharmaceutical medical device company focused on development of novel treatment modalities for difficult neurological conditions. Alcyone Lifesciences was founded in 2010 by PJ Anand, CEO, Alcyone Lifesciences, Dr. Adam Fleisher Associate Professor of Neuroscience, UCSD, Banner Alzheimer’s Institute and William Olbricht, PhD, Professor of Biomedical Engineering, Cornell University. For more information about Alcyone, please visit www.alcyonels.com.

About DNATrix

DNAtrix is a Houston-based, private biotechnology company focused on the development of oncolytic immunotherapy for the treatment of cancer. For more information about DNAtrix, please visit www.dnatrix.com.

Alcyone Life Sciences, Inc.
Contact PJ Anand
Founder, Chief Executive Officer
info@alcyonels.com
(978) 709-1946

DNAtrix, Inc. Contact
Frank Tufaro, Ph.D.
Chief Executive Officer
ftufaro@dnatrix.com
(858) 342-6577

HOUSTON, TX– October 23, 2012 – DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. (VLI), a company with a complementary intellectual property portfolio developing products for ovarian cancer. The merged company will retain the name DNAtrix and continue to develop its lead cancer product, DNX-2401, which is in clinical testing at the University of Texas M.D. Anderson Cancer Center for treating high grade brain tumors.

Dr. Imre Kovesdi, Ph.D., chief executive officer of VLI, and Dr. David T. Curiel, M.D., Ph.D., chief scientific officer and founder of VLI, will join the merged company as chief scientific officer and member of the Scientific Advisory Board, respectively.  “We are extremely pleased to join forces with Drs. Curiel and Kovesdi in this important effort,” stated Frank Tufaro, Ph.D., chief executive officer of the merged company.  “The merger makes strategic sense, and we are now a much stronger company in all respects.”

“As an inventor of VLI’s adenoviral technology,” stated Dr. Curiel. “I am very pleased to be able to work with the DNAtrix team in turning these discoveries into new cancer therapies.  This is a win-win for both companies.”

About Frank Tufaro, Ph.D., Chief Executive Officer

Dr. Tufaro serves as the chief executive officer of DNAtrix, Inc., where he has been since 2010 and has extensive experience in biotechnology.  He was CEO and co-founder of Neurovir, Inc., a Vancouver-based biotech company developing viral-based oncolytic vectors for treating cancer. Dr. Tufaro was instrumental in raising venture financing that established NeuroVir as the major player in the field of viral oncology and also helped negotiate and execute the successful merger of NeuroVir with MediGene AG. Prior to Neurovir, Dr. Tufaro was aUniversityofBritish Columbiavirology professor and holds a Ph.D. in molecular and development biology fromMcGillUniversity.

About Imre Kovesdi, Ph.D., Chief Scientific Officer

Dr. Kovesdi joins DNAtrix as chief scientific officer (CSO) and previously served as chief executive officer of VLI. Prior to joining VLI, he served as CSO with GenVec Inc. He joined GenVec in 1993 as one of its first employees and held several senior positions directing research, development and manufacturing before being appointed as CSO. Dr. Kovesdi was also a major contributor to GenVec’s intellectual property portfolio. Prior to joining GenVec, he led projects in the development of gene expression systems and therapeutic gene design at the Medical Research Division of the New York-based American Cyanamid Company. He holds a PhD in molecular biology from SimonFraserUniversityand a degree in electrical engineering from Universityof British Columbia. Dr. Kovesdi is the holder of over 100 US and foreign patents and has authored over 130 scientific articles in the areas of virology, gene delivery and molecular biology. Dr. Kovesdi has served on the boards of a number of biotechnology and information technology companies.

About David T. Curiel, M.D., Ph.D., Scientific Advisory Board member

Dr. Curiel joins DNAtrix as an advisor and previously served as chief scientific officer and founder of VLI.  Dr. Curiel is also presently the Director of Cancer Biology and theBiologicTherapyCenterat Washington University School of Medicine inSt. Louis. Previously he directed the Gene Therapy Center (GTC) of theUniversityofAlabamaat Birmingham (UAB) for 18 years. He holds an M.D. fromEmoryUniversitywhere he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland, at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI), a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch. He received his PhD from theUniversityofGroningen, in theNetherlands. He is a recognized leader in the field of vector development and in bench-to-bed translation of gene therapy and virotherapy interventions.

About DNX-2401

The company’s first product, DNX-2401, represents the culmination of over a decade of work and is the first oncolytic virus capable of killing cells with defects at any point in the retinoblastoma (Rb) pathway. DNX-2401 functions by replicating in, and killing tumor cells lacking growth control caused by any defect in the Rb pathway, without targeting a specific point in the pathway itself.  This property greatly lowers the risk of drug resistance and toxicity.  DNX-2401 is in clinical testing at University of Texas M.D. Anderson Cancer Center for treating glioblastoma multiforme, a type of stage IV brain tumor.  For more information about current clinical trials, please visit www.clinicaltrials.gov.

Glioblastoma multiforme (GB) is a fatal primary brain tumor resistant to conventional therapies. It is the second most common cause of death from intracranial disease, after stroke.  The current standard of care – surgery, radiotherapy and chemotherapy – has extended the overall median survival to only 14.6 months. GB is an unmet medical need with a clear need for new therapeutic modalities that can impact the course of the disease.

About VectorLogics, Inc.

VLI was founded by David Curiel, M.D., Ph.D. while at Universityof Alabama, Birmingham.  The Company was funded by Greer Capital for developing novel cancer therapies based on the inventions of Dr. Curiel, Dr. Kovesdi and others.

About DNAtrix, Inc.

DNAtrix is a Houston-based, private biotechnology company focused on the development of oncolytic virus technology for the treatment of cancer. It was founded in 2005 by a world class team of physicians and scientists;  Juan Fueyo, M.D., Candelaria Gomez-Manzano, M.D.,  Charles Conrad, M.D., Al Yun, M.D. and Frank McCormick, Ph.D.  DNAtrix has been funded to date by DFJ Mercury and the Texas Emerging Technology Fund. For more information about DNAtrix, please visit www.dnatrix.com.

DNAtrix, Inc. Contact
Frank Tufaro, Ph.D.
Chief Executive Officer
ftufaro@dnatrix.com
(858) 342-6577